EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

“Sandwich” protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study

Cheng-Qi Shen, Guo-Qian He, Zhi Wan, Chao Lin, Xue Yang, Xiao-Xi Lu, Yi-Ping Zhu, Ju Gao, Xia Guo

Annals of Hematology · 2023

DOI: 10.1007/s00277-023-05375-3 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Annals of Hematology, 2023. Verfasst von Cheng-Qi Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, West China Second University Hospital, Sichuan University, Section 3, South Renmin Road, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Science and Technology Program, Clinical Research Program of Sichuan Anti cancer Association (Qilu).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extranodal NK/T-cell lymphoma, nasal type (ENKTL), which is a rare form of mature T/NK cell lymphoma in children, currently lacks a standardized first-line treatment approach. However, a treatment protocol known as the “sandwich” regimen has been used in children newly diagnosed with ENKTL. This protocol combines the administration of methotrexate, ifosfamide, etoposide, pegaspargase, and dexamethasone (referred to as SMILE) with the addition of radiotherapy (RT). From September 2017 to December 2020, a total of five patients were included in the study, consisting of three males and two females. The median age of onset was 10.6 years (range, 9.8 to 14.0 years). Among the patients, four had nasal/nasopharyngeal disease at stage II, while one patient had extra nasal disease involving the skin at stage IV. The median EBV-DNA level in plasma was 1.68 × 10 3 copies/ml (range, 0.44 to 21.1 × 10 3 copies/ml). All the patients had good overall response after 2 cycles of chemotherapy and radiotherapy, including 4 of the patients who had a complete response and 1 of the patients with partial remission. The patient with stage IV received allogeneic hematopoietic stem cell transplantation after the EBV-DNA level was elevated again during treatment. One patient in the low-risk group experienced grade 4 oral mucositis, while no other severe complications or treatment-related deaths were observed. The median follow-up period was 22 months (range, 5 to 57 months). All five patients successfully completed their treatment, with four patients achieving event-free survival, and one patient was lost to follow-up. The median OS time and EFS time was 33 months (range: 18–57 months) and 20 months (range: 5–47 months), respectively. The sandwich protocol has demonstrated a high response rate, good tolerance to chemotherapy, and no treatment-related fatalities. However, further confirmation is necessary through additional clinical studies involving larger sample sizes. Clinical trial registration number: Due to modified SMILE regimens with sandwiched radiotherapy yielded promising outcomes in children ENKTL, we have carried out a phase II multicenter clinical trial (ChiCTR220005954) for children ENKTL in China to further verify the efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellMaleFemaleHumansChildAdolescentAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseCombined Modality TherapyMethotrexateDNATreatment OutcomeMulticenter Studies as Topic

Stichwörter der Autor:innen

ChildrenExtranodal NK/T-cell lymphomaNon-Hodgkin’s lymphomaSandwich therapy

Substanzen

AsparaginaseMethotrexateDNA

Autor:innen und Institutionen

  • Department of Pediatrics, West China Second University Hospital, Sichuan University, Section 3, South Renmin Road, Chengdu, 610041, China.
  • NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, 610041, China.
  • Department of Pediatrics, West China Second University Hospital, Sichuan University, Section 3, South Renmin Road, Chengdu, 610041, China. gaoju651220@126.com.
  • NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, 610041, China. gaoju651220@126.com.
  • Department of Pediatrics, West China Second University Hospital, Sichuan University, Section 3, South Renmin Road, Chengdu, 610041, China. guoxkl@163.com.
  • NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, 610041, China. guoxkl@163.com.

Förderung

  • Sichuan Science and Technology Program
  • Clinical Research Program of Sichuan Anti cancer Association (Qilu)

Zitieren

APA

Shen, C. Q., He, G. Q., Wan, Z., Lin, C., Yang, X., Lu, X. X., Zhu, Y. P., Gao, J., & Guo, X. (2023). “Sandwich” protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study. Annals of Hematology. https://doi.org/10.1007/s00277-023-05375-3

Vancouver

Shen CQ, He GQ, Wan Z, Lin C, Yang X, Lu XX, et al. “Sandwich” protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study. Annals of Hematology. 2023. doi:10.1007/s00277-023-05375-3

BibTeX
@article{Shen2023,
  author = {Shen, Cheng-Qi and He, Guo-Qian and Wan, Zhi and Lin, Chao and Yang, Xue and Lu, Xiao-Xi and Zhu, Yi-Ping and Gao, Ju and Guo, Xia},
  title = {“Sandwich” protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study},
  journal = {Annals of Hematology},
  year = {2023},
  doi = {10.1007/s00277-023-05375-3}
}
Kostenlos starten →